October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

Life science leaders with rounded corners lead to more enduring progress than razor-sharp perfection ever could, writes Tara ...

A major biopharmaceutical company faced equity and operational challenges from relying on temporary employees in long-term roles. These workers lacked full-time status and received limited, costly ...

Early-stage companies thrive on being nimble and running rather than walking. In times when funding is flowing and the IPO market is open, early partnering may be viewed with some skepticism out of ...

On this week's Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as ...

Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access. The question is no longer if, but how. Pharmaceutical companies ...

In today’s economic climate, companies are under increasing pressure to control costs, while still ensuring that legal risks are managed effectively. Whether you are running a lean legal department at ...

Clinical trials in rare disease and oncology settings demand more than scientific precision—they require a trauma-informed, patient-first mindset. Families navigating chronic, progressive illnesses ...

In rare oncology, patient-reported outcomes (PROs) are emerging as a vital tool for capturing the real-world impact of anti-cancer therapies. As traditional clinical endpoints often fall short in ...

On this week's episode, Lyle Small, Founder and CEO at Lahjavida, a dye drug conjugate start-up, talks about creating the famous color-changing technology that turned the mountains blue on cold Coors ...

Recently, the first patient in history was treated with an epigenetic editing therapy for facioscapulohumeral muscular dystrophy (FSHD). It was an extraordinary scientific milestone, but more ...